Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;25(11):1394-1405.
doi: 10.2174/0113892010260017231002075152.

Main Aspects of Pharmaceutical Development of In situ Immunobiological Drugs for Intranasal Administration

Elena Bakhrushina  1 , Iosif Mikhel  1 , Valeriya Kondratieva  2 , Natalia Demina  1 , Tatyana Grebennikova  2 , Ivan Krasnyuk Jr  1 , Ivan Krasnyuk  1
Affiliations
Review

Main Aspects of Pharmaceutical Development of In situ Immunobiological Drugs for Intranasal Administration

Elena Bakhrushina et al. Curr Pharm Biotechnol. 2024.

Abstract

Introduction: The review presents the latest developments in the area of intranasal in situ delivery systems of immunobiological drugs (IBDs). Interest in intranasal administration for IBDs has increased significantly due to the COVID-19 pandemic. However, not only intranasal delivery of vaccines is developing, but also bacteriophages, interferons, etc. In situ systems that make a selective phase transition can be a modern solution to intranasal delivery problems caused by mucociliary clearance. In addition, smart-polymers used as the main excipients in in situ systems can be used as specific adjuvants.

Methods: A scientific search was conducted on the PubMed database of medical publications for the period from 2000 to 2022, using the keywords "intranasal in situ vaccine"; "intranasal in situ immunization". There were analyzed in detail more than 70 scientific studies on intranasal in situ delivery of IBDs.

Results and conclusions: Despite the large number of new studies, the potential of possibilities of intranasal in situ systems is not being realized. Based on the results of the literature review an algorithm was created for the development of in situ systems for intranasal delivery of IBDs. Such algorithms and the methods of study design organization described in the review will help to facilitate the R&D process and bring the drug to commercial market, which will help to improve the quality of medical care.

Keywords: In situ systems; bacteriophages; immunobiological drugs; interferons.; intranasal administration; intranasal vaccines.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Vorob’ev AA; Liashenko, VA Immunobiological preparations: Their present and future. Immunobiol 2021,6,105-111
    1. Nagai M.; Moriyama M.; Ichinohe T.; Oral bacteria combined with an intranasal vaccine protect from influenza a virus and SARS-CoV-2 infection. MBio 2021,12(4),e01598-e21 - DOI - PubMed
    1. Xu H.; Cai L.; Hufnagel S.; Cui Z.; Intranasal vaccine: Factors to consider in research and development. Int J Pharm 2021,609,121180 - DOI - PubMed
    1. Buzitskaya Z.; Stosman K.; Khairullin B.; Kassenov M.; Nurpeisova A.; Abylai Sansyzbay A.; Shurygina A.P.; Aleksandrov A.; Sivak K.; Stukova M.; A new intranasal influenza vector-based vaccine TB/FLU-04L against tuberculosis: Preclinical safety studies. Drug Res 2022,72(5),255-258 - DOI - PubMed
    1. van der Ley P.A.; Zariri A.; van Riet E.; Oosterhoff D.; Kruiswijk C.P.; An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection. Front Immunol 2021,12,781280 - DOI - PubMed

LinkOut - more resources